Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan.
Thorac Cardiovasc Surg. 2021 Jan;69(1):101-108. doi: 10.1055/s-0039-1695784. Epub 2019 Sep 9.
Primary pulmonary sarcoma (PPS) is a rare malignant lung neoplasm, and there is very little medical evidence about treatment of PPS. The aim of this study is to clarify the clinical characteristics and therapeutic outcome of patients who underwent surgical resection for PPS.
We retrospectively reviewed the records of patients who underwent surgical resection for PPS in our institution between 1995 and 2014. Cases who only underwent biopsy were excluded.
A total of 24 patients (18 males, 6 females), with a median age of 60 (interquartile range: 44-67) years, were analyzed. The surgical procedures performed in these patients were pneumonectomy ( = 10), lobectomy ( = 11), and wedge resection ( = 3). Complete resection was achieved in 16 patients. The pathological stages (tumor, node, metastases lung cancer classification, 8th edition) of the patients were I ( = 4), II ( = 12), III ( = 2), and IV ( = 5), and there were four cases of lymph node metastasis. The 5-year overall survival rate of the patients was 50% (95% confidence interval [CI]: 29-72). Adverse prognostic factors for overall survival were incomplete resection (hazard ratio [HR]: 4.4, 95% CI: 2.1-42), advanced pathological stage (HR 14, 95% CI: 2.8-66), higher pathological grade (HR 4.5, 95% CI: 1.2-17), and tumor size ≥ 7 cm (HR 4.7, 95% CI: 1.1-21).
Our series of PPS revealed that incomplete resection, advanced pathological stage, higher pathological grade, and tumor size were unfavorable factors for long-term survival.
原发性肺肉瘤(PPS)是一种罕见的肺部恶性肿瘤,关于 PPS 的治疗方法,目前仅有很少的医学证据。本研究旨在阐明接受手术切除治疗的 PPS 患者的临床特征和治疗效果。
我们回顾性分析了 1995 年至 2014 年期间在我院接受手术切除治疗的 PPS 患者的病历资料。排除仅接受活检的病例。
共纳入 24 例患者(男 18 例,女 6 例),中位年龄为 60 岁(四分位间距:44-67 岁)。手术方式包括全肺切除术(n=10)、肺叶切除术(n=11)和楔形切除术(n=3)。16 例患者达到完全切除。患者的病理分期(第 8 版肺癌 TNM 分期)为Ⅰ期(n=4)、Ⅱ期(n=12)、Ⅲ期(n=2)和Ⅳ期(n=5),其中有 4 例发生淋巴结转移。患者的 5 年总生存率为 50%(95%置信区间:29-72)。影响总生存率的不良预后因素包括不完全切除(风险比[HR]:4.4,95%置信区间:2.1-42)、较高的病理分期(HR 14,95%置信区间:2.8-66)、较高的病理分级(HR 4.5,95%置信区间:1.2-17)和肿瘤直径≥7cm(HR 4.7,95%置信区间:1.1-21)。
本研究系列表明,不完全切除、较高的病理分期、较高的病理分级和肿瘤直径≥7cm 是影响长期生存的不利因素。